“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
How has patient advocacy grown to become the driver of rare disease drug development? In today's episode of Biorasi's Few & Far Between podcast,...
"We have to rethink the sense of clinical research from the point of view that if we have the possibility to have markers that...
On today’s podcast, Jimmy El Hokayem, Head of the Neurology and Regenerative Medicine Centers of Excellence and Associate Director of Program Development at Biorasi,...